573 related articles for article (PubMed ID: 16620137)
1. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
2. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
3. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B; Townsend MU
Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
[TBL] [Abstract][Full Text] [Related]
4. Tipranavir: a protease inhibitor for HIV salvage therapy.
Dong BJ; Cocohoba JM
Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
[TBL] [Abstract][Full Text] [Related]
5. Tipranavir: a ritonavir-boosted protease inhibitor.
Croom KF; Keam SJ
Drugs; 2005; 65(12):1669-77; discussion 1678-9. PubMed ID: 16060700
[TBL] [Abstract][Full Text] [Related]
6. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
11. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
12. Tipranavir: a review of its use in the management of HIV infection.
Orman JS; Perry CM
Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
[TBL] [Abstract][Full Text] [Related]
13. Tipranavir.
Plosker GL; Figgitt DP
Drugs; 2003; 63(15):1611-8. PubMed ID: 12887268
[TBL] [Abstract][Full Text] [Related]
14. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
15. Tipranavir: new drug. HIV protease inhibitor. A last resort.
Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
[TBL] [Abstract][Full Text] [Related]
16. Tipranavir: a novel second-generation nonpeptidic protease inhibitor.
Kandula VR; Khanlou H; Farthing C
Expert Rev Anti Infect Ther; 2005 Feb; 3(1):9-21. PubMed ID: 15757454
[TBL] [Abstract][Full Text] [Related]
17. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
18. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
[TBL] [Abstract][Full Text] [Related]
19. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
Temesgen Z; Feinberg J
Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
[TBL] [Abstract][Full Text] [Related]
20. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
Yeni P
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S91-4. PubMed ID: 14562864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
